New blood thinner may protect hearts during artery surgery
NCT ID NCT02505399
First seen Jan 06, 2026 · Last updated Jun 22, 2026 · Updated 22 times
Summary
This study tested whether a newer blood thinner, ticagrelor, works better than the standard clopidogrel in patients getting a procedure to clear hardened calcium from heart arteries. 180 adults with stable heart disease were randomly assigned to receive either drug before and after the procedure. Researchers measured troponin levels, a marker of heart muscle damage, to see if ticagrelor reduces injury.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATHEROSCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinique Pasteur
Toulouse, Haute-Garonne, 31000, France
-
Fédération de Cardiologie CHU TOULOUSE
Toulouse, Haute-Garonne, 31059, France
-
Hospices civils de Lyon
Lyon, 69000, France
-
University Hospital
Nîmes, 30000, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ticagrelor
What this could lead to
If ticagrelor works better than clopidogrel, it could reduce heart damage during this common procedure for hardened arteries.
What could go wrong
This is a small, completed Phase 4 trial. Ticagrelor may not show a meaningful benefit over clopidogrel, and it carries a risk of bleeding.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.